Novo Nordisk has almost doubled the scale of an R&D alliance with Valo Health – a specialist in applying artificial ...

Novo Nordisk’s collaboration with artificial intelligence startup Valo Health has focused on developing new drugs for cardiovascular disease. The pharmaceutical giant likes what it’s seen so ...

The deal expands a deal to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using human data and AI.

Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to develop new treatments for cardiometabolic diseases using human data and ...

Novo Nordisk and Valo Health have expanded their 16-month-old collaboration into an up-to-$4.6 billion-plus artificial intelligence (AI) partnership aimed at discovering and developing up to 20 ...

Novo Nordisk is doubling down on its collaboration with Valo Health, committing up to $190 million in near-term payments—and billions on the back end—to apply artificial intelligence to up to ...

At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish ...

The companies originally partnered in September 2023 in an agreement that allowed for the development of up to 11 drug programmes, primarily focused on cardiovascular disease, through which Valo was ...

Jan 8 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to develop new treatments for ...

Novo Nordisk Expands AI Partnership With Valo Health for Development of Obesity Drugs (Reuters) - Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding ...